Memantine Accord (Memantine Hydrochloride)

Memantine binds to the NMDA receptor channel at a site separate from the glutamate binding site, acting as a non‑competitive antagonist. This reduces excessive calcium influx caused by overstimulation, limiting excitotoxic neuronal damage and supporting synaptic function, which underlies its therapeutic effect in Alzheimer’s disease.

The specific dose and titration schedule for Memantine Accord are determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

The safety of memantine in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Memantine belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. While both improve symptoms, memantine is typically used in moderate to severe stages and targets glutamatergic excitotoxicity, whereas acetylcholinesterase inhibitors enhance cholinergic transmission and are often started earlier.

Memantine Accord should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Memantine Accord is taken orally, usually once daily after a meal to improve tolerability. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and emergent suicidal thoughts or mood changes. Patients should be monitored closely for any of these events, and immediate medical attention is required if they occur.

Memantine Accord is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or significant cardiac conduction disorders, and it should be avoided in those with a history of severe skin reactions to NMDA antagonists.